We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

35 hedge funds and large institutions have $32.6M invested in Axsome Therapeutics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more call options, than puts

Call options by funds: $207K | Put options by funds: $85K

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

17% more funds holding

Funds holding: 30 → 35 (+5)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

2% less capital invested

Capital invested by funds: $33.3M → $32.6M (-$674K)

2.58% less ownership

Funds ownership: 25.45% → 22.88% (-2.6%)

Holders
35
Holders Change
+5
Holders Change %
+16.67%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
6
Closed
4
Calls
$207K
Puts
$85K
Net Calls
+$122K
Net Calls Change
+$122K

Top Buyers

1
ACM
Alethea Capital Management
Washington
+$588K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$353K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$347K
4
Renaissance Technologies
Renaissance Technologies
New York
+$244K
5
Goldman Sachs
Goldman Sachs
New York
+$214K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.57M
2
SFM
Sphera Funds Management
Israel
-$1.01M
3
Millennium Management
Millennium Management
New York
-$223K
4
PAM
PVG Asset Management
Colorado
-$104K
5
Barclays
Barclays
United Kingdom
-$97K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
1
JP Morgan Chase
New York
$8.15M -$16.4K -3,253 -0.2%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$6.75M -$1.57M -310,400 -20%
RA
3
Royce & Associates
New York
$4.93M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$2.74M +$353K +69,830 +17%
Stifel Financial
5
Stifel Financial
Missouri
$2.33M – – –
SFM
6
Sphera Funds Management
Israel
$1.69M -$1.01M -200,000 -40%
OPPM
7
Opus Point Partners Management
New York
$748K – – –
Millennium Management
8
Millennium Management
New York
$705K -$223K -44,152 -26%
Allianz Asset Management
9
Allianz Asset Management
Germany
$704K – – –
ACM
10
Alethea Capital Management
Washington
$652K +$588K +116,500 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$527K – – –
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$385K +$347K +68,795 New
BCM
13
Bridgeway Capital Management
Texas
$280K – – –
Renaissance Technologies
14
Renaissance Technologies
New York
$271K +$244K +48,400 New
BlackRock
15
BlackRock
New York
$265K +$10.3K +2,040 +5%
Goldman Sachs
16
Goldman Sachs
New York
$238K +$214K +42,473 New
Mariner
17
Mariner
Kansas
$233K – – –
Northern Trust
18
Northern Trust
Illinois
$190K -$4.92K -974 -3%
Squarepoint
19
Squarepoint
New York
$176K -$11.1K -2,200 -7%
TI
20
Trexquant Investment
Connecticut
$128K +$116K +22,911 New
SAMH
21
Shanda Asset Management Holdings
British Virgin Islands
$112K +$101K +19,958 New
BWP
22
Baldwin Wealth Partners
Massachusetts
$109K – – –
JMFC
23
J.M. Forbes & Co
Massachusetts
$84K – – –
SSB
24
Sandy Spring Bank
Maryland
$49K – – –
Deutsche Bank
25
Deutsche Bank
Germany
$42K +$38.4K +7,600 +22,353%
1
2

AXSM Hedge Fund Activity: Q4 2017 in Review

35 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2017, worth a combined $32.6M — down 2% from $33.3M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new AXSM positions and 4 closed out — a net gain of 5 holders — while 7 added to existing stakes and 6 trimmed.

The largest buyer was Alethea Capital Management, opening a new position worth an estimated $588K. The largest seller was Fidelity Investments, cutting an estimated $1.57M.

  • 35 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2017, up from 30 in Q3 2017.
  • Funds reported $32.6M of Axsome Therapeutics stock for Q4 2017, down 2% quarter-over-quarter.
  • 9 funds opened new Axsome Therapeutics positions in Q4 2017 and 4 closed out, a net change of +5 holders.
  • The largest Axsome Therapeutics buyer in Q4 2017 was Alethea Capital Management, an estimated $588K added.
  • The largest Axsome Therapeutics seller in Q4 2017 was Fidelity Investments, an estimated $1.57M sold.

Based on aggregated 13F filings for Q4 2017.